Drug Treatment for Diabetes* Flashcards

1
Q

what are drugs that treat diabetes known as?

A

Hypoglycaemic Agents

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what is insulin?
what is it regulated by?

A

secreted by beta cells of the islets on Langerhans in pancreas
action –> lower blood glucose

Insulin section is regulated by:
- Glucose (most important)
- Glucagon
- GI hormones - due to eating – Incretins
- Products of digestion e.g. amino acids and fatty acids.
- Somatostatin hormone inhibits insulin secretion
- Parasympathetic/sympathetic nerve stimulation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what is the mechanism of secretion of insulin?

A
  1. Glucose enters Beta cells via transporter molecules
  2. Glucose metabolism increases intracellular ATP concentration => inhibits the activity of ATP sensitive K+ channels (KATP)
  3. KATP: a complex made up of a K+ channel & sulphonylurea receptor (SUR)
  4. This results in depolarisation of the cell as K+ efflux is reduced
  5. Depolarisation causes voltage gated Ca2+ channels to open
  6. Rise in intracellular Ca2+ causes insulin secretion via exocytosis
  7. (Diacylglycerol) DAG regulates insulin secretion by controlling the pathway that vesicles are secreted.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

how is insulin released in the body?

A

t=0 => Glucose injection
Normal Person:
First rapid phase of insulin secretion (via exocytosis ),
Second phase (promoted by enzyme action) - slower in order to normalise blood sugar levels over a long term
Lack of both first and second phase in T1 DM
lack of first rapid phase of insulin secretion T2 DM

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

describe the structure of and Insulin receptor (in liver, muscle & fat) = RTK (tyrosine kinase)

A

Heterodimer:
- 2 alpha subunits forming the extracellular binding domains
- 2 beta subunits forming transmembrane tyrosine kinases

  • Because 2 alpha subunits & 2 insulin molecules have to bind for a response
  • Binding of insulin molecules causes phosphorylation of insulin receptor substrate proteins (IRS proteins) by tyrosine kinase
  • This produces a cascade causing enzyme activation & gene transcription
  • Increase expression of Glut-4 (glucose transporter) results in increased glucose uptake
    Increased glycogen synthesis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

define onset, peak and duration in the context of insulin

A

Onset – How quickly insulin lowers your blood sugar.
Peak Time – When insulin is at maximum strength.
Duration – How long insulin works to lower your blood sugar.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

what is insulin therapy?

A

insulin is a peptide hormone so it administered parenterally (non-orally - subcutaneous pump, intramuscularly; intravenously)
Insulin has a short half-life: T1/2 = 5 mins
Medical insulin is produced from recombinant DNA being inserted into bacteria (although some = porcine – pigs pancreas)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what is the duration of action of insulin?

A

Duration of insulin action is determined by controlling the rate of insulin absorption into blood once injected into tissue

Short acting (pre-meal):
Onset: 30min; peak: 1-2 hrs
Short acting insulin is absorbed faster into the blood
Types: Soluble insulin or Insulin Lispro
Insulin lispro faster as it is less likely to aggregate (insulin molecules have tendency to bind together)

Long acting:
onset: 1-2 hrs; peak: 4-12 hrs
Type: Insulin complex or insulin glargine
Insulin Complex: when insulin is combined with protamine or zinc, => allows slower absorption of insulin into blood
Insulin Glargine = insulin molecules bind to each other forming micro-precipitates => allows for slower absorption into blood

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what are the 3 different Insulin dose regimes?

A
  1. Short acting (x3 a day) - before each meal and then Intermediate/long acting (x1-2 a day).
    This is known as the basal-bolus regime
  2. You can also get pre-mixed short acting with intermediate/long acting insulins (x1-2 a day)
    This reduces the number of injections required per day
  3. Continuous Insulin infusion (Insulin pump therapy): This delivery method mimics nondiabetic insulin delivery - delivers a slow basal rate throughout the 24 h with patient-activated boosts at mealtimes. This could be very helpful for people with uncontrolled diabetes.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what are some Insulin Therapy Complications?

A

Hypoglycaemia (symptoms hard to detect in elderly)
Allergies to insulin
Lipodystrophy – wasting or synthesis of adipose tissue at the injection site. Therefore the site is regularly altered by diabetics to avoid this

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what is type 2 diabetes mellitus?

A
  • Linked to Obesity, hypertension, hyperlipidaemia (abnormally high levels of fats (lipids) in the blood)
  • Usually initially developed in patients older than 25
  • Less severe than T1 DM (Glucose levels don’t get as high as type 1)
  • Loss of 1st phase of insulin secretion (rapid secretion)
  • Higher basal insulin compared to non-diabetic (however still insufficient due to insensitivity)
  • Insulin resistance of tissue is the main problem
  • Insulin resistance is associated with inflammation in adipose tissue
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what are the different Oral Hypoglycaemic Agents? (MATMIS)

A

Metformin
Sulphonylureas (SU)
Meglitinides
Thiazolidinediones (TZD)
Acarbose
Drugs based on Incretin Actions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

what is metformin?

A

Used to manage T2 DM but can be given to T1 DM.

Mechanism - requires insulin to be taken alongside it
Work at the Liver/muscle
Decreased gluconeogenesis at the liver. This is done via the activation of AMP-activated protein kinase. This decreases gene expression for genes involved in gluconeogenesis
It also results in increased glucose uptake by the muscles

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what are the side effects of metformin?

A

Side effects:
no hypoglycaemia
no increased appetite
cause lactic acidosis - occurs when lactic acid production exceeds lactic acid clearance (reversible once drug stopped)
It is used by obese diabetics in combination with other drugs
GMC recommends metformin as first line treatment following failure to control T2 DM via lifestyle changes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what are Sulphonylureas (SU)?

A

i.e. tolbutamide, glibenclamide, gliclazide
Used in Type 2 diabetics, ineffective in T1 DM

Mechanism:
Act on B cells => bind to SU receptor component of KATP => binding causes channel to close (similar to effect of increased ATP) 🡪 depolarisation => increased insulin secretion
Secondary effect => increased tissue sensitivity to insulin (effective for type 2 diabetics)
Duration of action (variations due to half-life)
Long i.e. glibenclamide => it is an active metabolite of the breakdown of the drug, so longer lasting (1x a day)
Short i.e. tolbutamide (3 x a day)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what is the mechanism of other SUR modulators i.e. meglitinides?

A

(e.g. repaglinide)

Mechanism:
Doesn’t act in same way as SUs, but has same effect => binds to SUR => decreases KATP activity => increases insulin secretion
Shorter duration of action => has a weaker affinity for SUR so dissociate more readily
They are however more selective for KATP channels in beta cells and not in other cells (as KATP found in e.g. muscle cells)

17
Q

what are the side effects of SUR drugs?

A

Hypoglycaemia (esp. with other drugs); less with repaglinide
Stimulates appetite (not good for obese patients)
Contraindicated in pregnancy/breast feeding
Can cross the placenta and effect the foetus.
Affect insulin production of new born being breast fed.

18
Q

what is the mechanism of Thiazolidinediones (TZD)?

A

i.e. pioglitazone - used in combination with metformin or SU

Mechanism: binds to transcription factor –> affects gene expression in various tissues
primary action in adipose tissue –> increased fatty acid uptake & increased lipogenesis (causes weight gain, so contraindicated in obese)
secondary action (main reason used): decreases fatty acids in plasma which promotes increased glucose uptake and decreased gluconeogenesis

19
Q

what are the side effects of Thiazolidinediones (TZD)?

A

(less commonly used in practice due to side effects)

weight gain
liver toxicity
Causes fluid retention which leads to heart failure; bladder cancer

20
Q

what are drugs based on Incretin Actions?

A

Incretins are GI hormones (i.e. Glucagon like peptides)
Mechanism: Released into the GI tract when people eat a meal –> act on pancreas –> cause increase insulin secretion and decrease in glucagon secretion.

Drugs:
1. Inhibitors of dipeptidyl peptidase-4 (transmembrane), enzymes which metabolise incretins
- Gliptins (linagliptin) (oral) is an example of an inhibitor –> block breakdown of incretins which results in the reduction of glucose levels

  1. GLP-1 (incretin) agonists (exenatide): They are s.c. injected as they are peptides. They increase insulin secretion and also allow for slow gastric emptying (good for obese people as they are fuller for longer – BMI >35)
    Incretins are expensive so used in combination
21
Q

what are Acarbose?

A

An alpha-glucosidase inhibitor which works in the gut to inhibit an enzyme involved in metabolism of carbohydrates –> decreased carbohydrate absorption in gut –> reduced glucose levels
used for obese people either alone or w/ metformin

22
Q

what is the mechanism of SGLT2 (Sodium glucose transporter-2) inhibitors?

(idk if this is oral hypoglycemic agent)

A

Na-glucose transporter-2 inhibitors i.e. canagliflozin (usually used in combination with other drugs)

Mechanism:
Act on the Proximal convoluted tube in the kidney –> inhibit SGLT2 –> decreased glucose reabsorption –> more glucose and Na+ (not too good) excreted in the urine

23
Q

what are the side effects of SGLT2 (Sodium glucose transporter-2) inhibitors?

A

side effects:
Peripheral vascular disease (narrowing of blood vessels at peripheral tissue which can lead to amputation of limbs – so won’t be used for people who already have impairment of blood flow to peripheral tissue).
Also Na+ (osmotic agent) loss will cause a loss of water in the blood –> reduction in blood volume (hypovolaemia) –> enhances effects.
No glucose for energy so lipids used –> increased ketone bodies in blood => ketoacidosis